Prescient appoints Nick Edwards and Nader Naeymi-Rad to the Board of Directors.

LONDON, October 24, 2017—Prescient Healthcare Group, a global product strategy and decision support consultancy, announces the recent appointments of Nick Edwards and Nader Naeymi-Rad to the Board of Directors, further strengthening its foundation for continued success.

Edwards serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Edwards practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Edwards served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

“I am delighted to be joining Prescient and look forward to continuing to serve the pharmaceutical industry,” Edwards said. “There are many new drugs coming to market with great potential; I look forward to working with our clients to help realize their full clinical and economic benefits.”

Naeymi-Rad serves on Prescient’s Board as a Non-Executive Director. He has a BA from Georgetown University. He was previously the Chief Executive Officer of Campbell Alliance, where he oversaw all of the firm’s business units to ensure its continued growth, commitment to client service, development of new service lines and geographic expansion. Naeymi-Rad is an expert in developing and implementing business strategy, process improvement and business development solutions for clients in the pharmaceutical and biotechnology industries.

“The life sciences industry continues to push the boundaries of science to bring better care and outcomes to millions of patients around the world,” Naeymi-Rad said. “I am very pleased to be able to leverage my knowledge and experience to help the members of the Prescient team as they help their clients bring better medicines to market.”

“Developing targeted and differentiated clinical and commercial value propositions is at the heart of what we do,” said Jamie Denison-Pender, CEO, Prescient. “I am thrilled Nick and Nader have joined us. Both bring breadth and depth of experience from their previous roles, and we are excited to leverage their methodological and strategic expertise to continue bringing value to our clients and growing the company.”

Biographies and contact information for both Nick Edwards and Nader Naeymi-Rad can be found on our recently relaunched website: